Cargando…

Early Economic Assessment of Faecal Microbiota Transplantation for Patients with Urinary Tract Infections Caused by Multidrug-Resistant Organisms

INTRODUCTION: The use of faecal microbiota transplantation (FMT) to eradicate intestinal carriage of multidrug-resistant organisms (MDRO) has been described in case reports and small case series. Although few in numbers, these patients suffer from recurrent infections that may exacerbate both the pa...

Descripción completa

Detalles Bibliográficos
Autores principales: Baek, Olivia Dybro, Hjermitslev, Camilla K., Dyreborg, Line, Baunwall, Simon M. D., Høyer, Katrine L., Rågård, Nina, Hammeken, Lianna H., Povlsen, Johan V., Ehlers, Lars H., Hvas, Christian Lodberg
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10229483/
https://www.ncbi.nlm.nih.gov/pubmed/37062804
http://dx.doi.org/10.1007/s40121-023-00797-y
_version_ 1785051266901082112
author Baek, Olivia Dybro
Hjermitslev, Camilla K.
Dyreborg, Line
Baunwall, Simon M. D.
Høyer, Katrine L.
Rågård, Nina
Hammeken, Lianna H.
Povlsen, Johan V.
Ehlers, Lars H.
Hvas, Christian Lodberg
author_facet Baek, Olivia Dybro
Hjermitslev, Camilla K.
Dyreborg, Line
Baunwall, Simon M. D.
Høyer, Katrine L.
Rågård, Nina
Hammeken, Lianna H.
Povlsen, Johan V.
Ehlers, Lars H.
Hvas, Christian Lodberg
author_sort Baek, Olivia Dybro
collection PubMed
description INTRODUCTION: The use of faecal microbiota transplantation (FMT) to eradicate intestinal carriage of multidrug-resistant organisms (MDRO) has been described in case reports and small case series. Although few in numbers, these patients suffer from recurrent infections that may exacerbate both the patients’ comorbidities and their healths. In the current study, we hypothesized that FMT for MDRO-related urinary tract infections (UTIs) reduces hospitalisations and associated costs. METHODS: In a cohort of patients referred for FMT from 2015 to 2020, we selected all patients who had consecutively been referred for eradication of MRDO carriage with UTIs. An early economic assessment was performed to calculate hospital-related costs. The overall study cohort was registered at ClinicalTrials, study identifier NCT03712722. RESULTS: We consecutively included five patients with UTIs caused by MDROs. Four of the patients were renal transplant recipients. Patients were followed for median 126 days (range 60–320), where the follow-up duration for each patient was aligned with the number of days from the first UTI to FMT. The median number of UTIs per patient dropped from 4 to 0. Investigating hospital costs, hospital admission days dropped by 87% and monthly hospital costs by 79%. CONCLUSIONS: FMT was effective in reducing the occurrence of UTIs and mediated a marked reduction in hospital costs. We suggest that this strategy is cost-effective. TRIAL REGISTRATION: ClinicalTrials, study identifier NCT03712722. GRAPHICAL ABSTRACT: [Image: see text]
format Online
Article
Text
id pubmed-10229483
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Springer Healthcare
record_format MEDLINE/PubMed
spelling pubmed-102294832023-06-01 Early Economic Assessment of Faecal Microbiota Transplantation for Patients with Urinary Tract Infections Caused by Multidrug-Resistant Organisms Baek, Olivia Dybro Hjermitslev, Camilla K. Dyreborg, Line Baunwall, Simon M. D. Høyer, Katrine L. Rågård, Nina Hammeken, Lianna H. Povlsen, Johan V. Ehlers, Lars H. Hvas, Christian Lodberg Infect Dis Ther Brief Report INTRODUCTION: The use of faecal microbiota transplantation (FMT) to eradicate intestinal carriage of multidrug-resistant organisms (MDRO) has been described in case reports and small case series. Although few in numbers, these patients suffer from recurrent infections that may exacerbate both the patients’ comorbidities and their healths. In the current study, we hypothesized that FMT for MDRO-related urinary tract infections (UTIs) reduces hospitalisations and associated costs. METHODS: In a cohort of patients referred for FMT from 2015 to 2020, we selected all patients who had consecutively been referred for eradication of MRDO carriage with UTIs. An early economic assessment was performed to calculate hospital-related costs. The overall study cohort was registered at ClinicalTrials, study identifier NCT03712722. RESULTS: We consecutively included five patients with UTIs caused by MDROs. Four of the patients were renal transplant recipients. Patients were followed for median 126 days (range 60–320), where the follow-up duration for each patient was aligned with the number of days from the first UTI to FMT. The median number of UTIs per patient dropped from 4 to 0. Investigating hospital costs, hospital admission days dropped by 87% and monthly hospital costs by 79%. CONCLUSIONS: FMT was effective in reducing the occurrence of UTIs and mediated a marked reduction in hospital costs. We suggest that this strategy is cost-effective. TRIAL REGISTRATION: ClinicalTrials, study identifier NCT03712722. GRAPHICAL ABSTRACT: [Image: see text] Springer Healthcare 2023-04-16 2023-05 /pmc/articles/PMC10229483/ /pubmed/37062804 http://dx.doi.org/10.1007/s40121-023-00797-y Text en © The Author(s) 2023 https://creativecommons.org/licenses/by-nc/4.0/Open AccessThis article is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) .
spellingShingle Brief Report
Baek, Olivia Dybro
Hjermitslev, Camilla K.
Dyreborg, Line
Baunwall, Simon M. D.
Høyer, Katrine L.
Rågård, Nina
Hammeken, Lianna H.
Povlsen, Johan V.
Ehlers, Lars H.
Hvas, Christian Lodberg
Early Economic Assessment of Faecal Microbiota Transplantation for Patients with Urinary Tract Infections Caused by Multidrug-Resistant Organisms
title Early Economic Assessment of Faecal Microbiota Transplantation for Patients with Urinary Tract Infections Caused by Multidrug-Resistant Organisms
title_full Early Economic Assessment of Faecal Microbiota Transplantation for Patients with Urinary Tract Infections Caused by Multidrug-Resistant Organisms
title_fullStr Early Economic Assessment of Faecal Microbiota Transplantation for Patients with Urinary Tract Infections Caused by Multidrug-Resistant Organisms
title_full_unstemmed Early Economic Assessment of Faecal Microbiota Transplantation for Patients with Urinary Tract Infections Caused by Multidrug-Resistant Organisms
title_short Early Economic Assessment of Faecal Microbiota Transplantation for Patients with Urinary Tract Infections Caused by Multidrug-Resistant Organisms
title_sort early economic assessment of faecal microbiota transplantation for patients with urinary tract infections caused by multidrug-resistant organisms
topic Brief Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10229483/
https://www.ncbi.nlm.nih.gov/pubmed/37062804
http://dx.doi.org/10.1007/s40121-023-00797-y
work_keys_str_mv AT baekoliviadybro earlyeconomicassessmentoffaecalmicrobiotatransplantationforpatientswithurinarytractinfectionscausedbymultidrugresistantorganisms
AT hjermitslevcamillak earlyeconomicassessmentoffaecalmicrobiotatransplantationforpatientswithurinarytractinfectionscausedbymultidrugresistantorganisms
AT dyreborgline earlyeconomicassessmentoffaecalmicrobiotatransplantationforpatientswithurinarytractinfectionscausedbymultidrugresistantorganisms
AT baunwallsimonmd earlyeconomicassessmentoffaecalmicrobiotatransplantationforpatientswithurinarytractinfectionscausedbymultidrugresistantorganisms
AT høyerkatrinel earlyeconomicassessmentoffaecalmicrobiotatransplantationforpatientswithurinarytractinfectionscausedbymultidrugresistantorganisms
AT ragardnina earlyeconomicassessmentoffaecalmicrobiotatransplantationforpatientswithurinarytractinfectionscausedbymultidrugresistantorganisms
AT hammekenliannah earlyeconomicassessmentoffaecalmicrobiotatransplantationforpatientswithurinarytractinfectionscausedbymultidrugresistantorganisms
AT povlsenjohanv earlyeconomicassessmentoffaecalmicrobiotatransplantationforpatientswithurinarytractinfectionscausedbymultidrugresistantorganisms
AT ehlerslarsh earlyeconomicassessmentoffaecalmicrobiotatransplantationforpatientswithurinarytractinfectionscausedbymultidrugresistantorganisms
AT hvaschristianlodberg earlyeconomicassessmentoffaecalmicrobiotatransplantationforpatientswithurinarytractinfectionscausedbymultidrugresistantorganisms